The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making.

Autor: Mansfield C; Department of Health Preference Assessment, RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC, 27709, USA. carolm@rti.org., Bullok K; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Fuhs JV; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Tockhorn-Heidenreich A; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Andrews JS; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.; Takeda Pharmaceuticals, Cambridge, MA, USA., DiBenedetti D; Department of Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USA., Matthews BR; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Darling JC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.; Seagen Inc, Bothell, WA, USA., Sutphin J; Department of Health Preference Assessment, RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC, 27709, USA.; Duke Clinical Research Institute, Duke University, Durham, NC, USA., Hauber B; Department of Health Preference Assessment, RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC, 27709, USA.; Pfizer, Inc., and the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA, USA.

Publikováno v: The patient [Patient] 2022 Sep; Vol. 15 (5), pp. 551-564. Date of Electronic Publication: 2022 Apr 18.

Correction to: Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study.

Autor: Jimenez-Moreno AC; Translational and Clinical Research Institute, Newcastle University, Newcastle-Upon-Tyne, UK. jimenez.moreno.aura.cecilia@gmail.com.; Evidera, London, UK. jimenez.moreno.aura.cecilia@gmail.com., van Overbeeke E; Clinical Pharmacology and Pharmacotherapy, University of Leuven, Leuven, Belgium., Pinto CA; Pharmacoepidemiology Department, Center for Observational and Real-world Evidence, Merck & Co, Inc., Rahway, NJ, USA., Smith I; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Sharpe J; Muscular Dystrophy UK, London, UK., Ormrod J; School of Applied Social Science, University of Brighton, East Sussex, UK., Whichello C; Erasmus School of Health Policy and Management, and Erasmus Choice Modelling Centre, Erasmus University, Rotterdam, The Netherlands., de Bekker-Grob EW; Erasmus School of Health Policy and Management, and Erasmus Choice Modelling Centre, Erasmus University, Rotterdam, The Netherlands., Bullok K; Global Patient Safety Department, Eli Lilly & Co., Indianapolis, IN, USA., Levitan B; Janssen Research and Development, Titusville, NJ, USA., Huys I; Clinical Pharmacology and Pharmacotherapy, University of Leuven, Leuven, Belgium., de Wit GA; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Gorman G; Translational and Clinical Research Institute, Newcastle University, Newcastle-Upon-Tyne, UK.

Publikováno v: The patient [Patient] 2021 Sep; Vol. 14 (5), pp. 693.

In vivo scanning laser fundus and high-resolution OCT imaging of retinal ganglion cell injury in a non-human primate model with an activatable fluorescent-labeled TAT peptide probe.

Autor: Qiu, Xudong¹ (AUTHOR), Gammon, Seth T.¹ (AUTHOR), Rasmussen, Carol² (AUTHOR), Pisaneschi, Federica¹ (AUTHOR), Kim, Charlene B. Y.² (AUTHOR), Ver Hoeve, James² (AUTHOR), Millward, Steven W.¹ (AUTHOR), Barnett, Edward M.³ (AUTHOR), Nork, T. Michael² (AUTHOR), Kaufman, Paul L.² (AUTHOR), Piwnica-Worms, David¹ (AUTHOR) dpiwnica-worms@mdanderson.org

Publikováno v: PLoS ONE. 12/6/2024, Vol. 19 Issue 12, p1-19. 19p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Incorporation of a Benefit-Risk Assessment Framework Into the Clinical Overview of Marketing Authorization Applications.

Autor: Wolka A; 1 Eli Lilly and Company, Indianapolis, IN, USA., Warner M; 1 Eli Lilly and Company, Indianapolis, IN, USA., Bullok K; 1 Eli Lilly and Company, Indianapolis, IN, USA., Wang J; 1 Eli Lilly and Company, Indianapolis, IN, USA., Radawski C; 1 Eli Lilly and Company, Indianapolis, IN, USA., Noel R; 1 Eli Lilly and Company, Indianapolis, IN, USA.

Publikováno v: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2016 Jan; Vol. 50 (1), pp. 130-134.